World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
133
Citations
85474
World Ranking
2186
National Ranking
1235

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

John M. Kirkwood is affiliated with the University of Pittsburgh in the United States. Their research primarily spans the fields of Medicine as well as Biochemistry, Genetics and Molecular Biology, with a significant focus on oncology-related studies.

Their extensive publication record includes work in major scientific journals, reflecting a focus on oncology and immunology topics. The most frequent publication venues for their research are:

  • Journal of Clinical Oncology
  • Cancer Research
  • Regular and Young Investigator Award Abstracts
  • Journal for ImmunoTherapy of Cancer
  • Annals of Oncology

The primary subfields of John M. Kirkwood's research cover:

  • Oncology
  • Immunology
  • Molecular Biology
  • Ophthalmology
  • Epidemiology

The main topics addressed in their work include:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Cutaneous Melanoma Detection and Management
  • Immunotherapy and Immune Responses
  • Melanoma and MAPK Pathways
  • Ocular Oncology and Treatments
  • Immune Cell Function and Interaction

John M. Kirkwood has collaborated frequently with several co-authors, including:

  • Cindy Sander
  • Diwakar Davar
  • Ahmad A. Tarhini
  • Georgina V. Long
  • Jason J. Luke

Some notable recent publications from John M. Kirkwood's research include:

  • "Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients" (2021), published in Science
  • "Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma" (2021), published in New England Journal of Medicine
  • "Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma" (2023), published in New England Journal of Medicine
  • "Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma" (2020), published in New England Journal of Medicine
  • "Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134" (2022), published in Journal of Clinical Oncology

Among professional recognitions, John M. Kirkwood is a member of the Association of American Physicians.

Best Publications

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

    Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen

  • Final Version of 2009 AJCC Melanoma Staging and Classification

    Charles M. Balch;Jeffrey E. Gershenwald;Seng Jaw Soong;John F. Thompson

  • Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

    John M. Kirkwood;Myla Hunt Strawderman;Marc S. Ernstoff;Thomas J. Smith

  • Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

    Jeffrey E. Gershenwald;Richard A. Scolyer;Kenneth R. Hess;Vernon K. Sondak

  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    Antoni Ribas;Igor Puzanov;Reinhard Dummer;Dirk Schadendorf

  • Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

    Julien Fourcade;Zhaojun Sun;Mourad Benallaoua;Philippe Guillaume

  • Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients

    Diwakar Davar;Amiran K. Dzutsev;John A. McCulloch;Richard R. Rodrigues

  • Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

    Antoni Ribas;Reinhard Dummer;Igor Puzanov;Ari VanderWalde

  • Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

    G. V. Long;A. Hauschild;M. Santinami;V. Atkinson

  • High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801

    John M. Kirkwood;Joseph G. Ibrahim;Jeffrey A. Sosman;Vernon K. Sondak

  • Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

    Grant A McArthur;Paul B Chapman;Caroline Robert;James Larkin

  • High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190

    John M. Kirkwood;Joseph G. Ibrahim;Vernon K. Sondak;Jon Richards

  • Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

    Georgina V. Long;Uwe Trefzer;Michael A. Davies;Richard F. Kefford

  • TIGIT and PD-1 impair tumor antigen–specific CD8 + T cells in melanoma patients

    Joe-Marc Chauvin;Ornella Pagliano;Julien Fourcade;Zhaojun Sun

  • The role of BRAF V600 mutation in melanoma

    Paolo A. Ascierto;John M. Kirkwood;Jean Jacques Grob;Ester Simeone

  • Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

    Antoni Ribas;Richard Kefford;Margaret A. Marshall;Cornelis J.A. Punt

  • Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

    Edward L. Korn;Ping Yu Liu;Sandra J. Lee;Judith Anne W. Chapman

  • Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

    Axel Hauschild;Sanjiv S. Agarwala;Uwe Trefzer;David Hogg

  • Prognostic significance of autoimmunity during treatment of melanoma with interferon

    Michal T. Krauze;Ahmad Tarhini;Helen Gogas;John M. Kirkwood

  • Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group

    Agop Y. Bedikian;Michael Millward;Hubert Pehamberger;Robert Conry

Frequent Co-Authors

Ahmad A. Tarhini
Ahmad A. Tarhini Cleveland Clinic
Marc S. Ernstoff
Marc S. Ernstoff Roswell Park Cancer Institute
Vernon K. Sondak
Vernon K. Sondak University of South Florida
Georgina V. Long
Georgina V. Long University of Sydney
Lisa H. Butterfield
Lisa H. Butterfield University of California, San Francisco
Reinhard Dummer
Reinhard Dummer University of Zurich
Antoni Ribas
Antoni Ribas University of California, Los Angeles
Michael B. Atkins
Michael B. Atkins Georgetown University
Keith T. Flaherty
Keith T. Flaherty Harvard University
Axel Hauschild
Axel Hauschild Kiel University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in medicine but want flexible or alternative career options? Online degrees in healthcare are rapidly expanding, offering accelerated routes into the medical field. For those aiming to enter the workforce quickly, online lpn programs provide a pathway to become a Licensed Practical Nurse in a short amount of time.

If you’re interested in mental health, advanced practice is possible through specialized tracks like online psych np programs. These programs prepare nurses for roles in psychiatric care, directly supporting patients with mental health needs.

Prefer to blend medicine with leadership? Consider pursuing a health administration degree. This credential is ideal for those who want to manage healthcare operations rather than provide direct patient care.

Advancing further, affordable graduate options such as affordable online mha programs can help you qualify for highly sought-after management roles in hospitals, clinics, or public health organizations—often with flexible online learning.

Best Scientists Citing John M. Kirkwood

Trending Scientists